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Abstract
Background: Currently available Interferon-gamma release assays (IGRAs) show a considerable variability in serial
testing for latent tuberculosis infection (LTBI).
This study offers first results for the new generation IGRA QuantiFERON-TB Gold Plus (QFT-Plus) introduced in 2015
in comparison with its predecessor QuantiFERON-TB Gold In-Tube (QFT-GIT) from serial testing of students with a
migration background at German universities.
Methods: Forty-one students were selected from a previous study. All students with a positive IGRA were asked
and 11 agreed to participate in this cohort study. Additionally 30 students with negative IGRA results were selected
by chance. Weekly testing with QFT-Plus and QFT-GIT was performed in all individuals over a 4-week period. IGRA
variability was evaluated by calculating conversion and reversion rates.
Results: From 41 participants a total number of 163 serial measurements were analyzed for each IGRA, leading to
122 possible IGRA changes each. QFT-Plus had four conversions and two reversions leading to a conversion rate of
4.3% (4 of 93 possible conversions, 95% CI 1.4–11.3%) and reversion rate of 6.9% (2 of 29 possible reversions, 95% CI
1.2–24.2%). QFT-GIT had 2 conversions and 1 reversion causing slightly lower rates with 2.2% conversions (2 of 91,
95% CI 0.4–8.5%) and 3.2% reversions (1 of 31, 95% CI 0.2–18.5%). Inconsistent IGRA results occurred in 4 subjects
for QFT-Plus (8 stable positives, 29 stable negatives) and in 2 subjects for QFT-GIT (9 stable positives, 30 stable
negatives). Agreement between the two IGRAs was 95.1% (κ = 0.89). Variance attributed to the individuals was low
(QFT-Plus: ICC = 0.88).
Conclusion: This study confirms occurrence of conversions and reversions for the new QFT-Plus in serial testing of
a high-risk cohort in a low-incidence setting with improbable new TB contact during the study. QFT-Plus
conversion and reversion rates were slightly higher than for the QFT-GIT but overall they were lower for both IGRAs
than in other studies that investigated IGRA variability.
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Background
Since its first approval by the U.S. Food and Drug
Administration (FDA) in 2001 [1] hopes were high for
the Interferon-gamma release assay (IGRA) as a new
method to test for latent tuberculosis infection (LTBI).
Meanwhile, for over a decade IGRAs have played an
important role in global tuberculosis control as they
offer a convenient way to screen for LTBI. They are
increasingly used in high-income countries instead of
the tuberculin skin test (TST) for LTBI-testing.
IGRAs have major advantages over the TST, such as
delivering results after 24 h with no need for a second
appointment, not being affected by the examiner’s
subjectivity that may influence TST interpretation, not
struggling as an in vitro test with the problem of boost-
ing in subsequent tests, using a positive control to facili-
tate interpretation in immunocompromised subjects and
not cross-reacting with most nontuberculous mycobac-
teria (NTM) or BCG vaccine strains [2]. The latter
improvement should lead to a higher specificity in BCG
vaccinated subjects while maintaining a good sensitivity
like that of the TST [3–5].
Beside their advantages over TST, IGRAs tend to show
a high variability with high rates of conversions and
reversions in serial testing, which was shown to be
present in low as well as high TB incidence settings [6, 7].
Tagmouti et al. notice in a systematic review that IGRA
test variability is higher than TST variability [8]. In settings
where serial IGRA testing for LTBI is done, the elevated
test variability leads to uncertainty whether chest X-ray or
preventive chemotherapy is needed in the event of a posi-
tive test result with the knowledge that reversions tend to
occur more frequently than conversions [8–11].
Following results from recent studies, several guidelines
step back from promoting IGRAs as the standalone test
for serial LTBI screening. Canada’s 2013 guideline update
recommends TST rather than IGRA for testing low-risk
individuals, noting that IGRA is not recommended for
serial testing for populations with ongoing exposure [12].
The 2010 updated U.S. guidelines allow either TST or
IGRA as the method of choice for serial testing, pointing
out that using IGRA might lead to higher conversion rates
making it difficult to identify IGRA changes that truly
represent a new infection [13]. In Europe the ECDC
guidelines allow IGRA as a baseline test, likewise pointing
out problems of increased test variability offering a two-
step approach in order to increase specificity [14].
Pai et al. postulate the simple dichotomous definition
of IGRA test results to be inappropriate as it causes
higher conversion rates than what the annual TB infec-
tion risk in low-incidence settings would lead to expect
[15]. Several studies suggest the use of a borderline zone
in order to avoid unnecessary X-rays and preventive
chemotherapy [9, 16–20].
Until recently two IGRAs were commercially available,
QuantiFERON-TB Gold In-Tube (QFT-GIT) (Qiagen,
Hilden, Germany) and T-SPOT.TB (Oxford Immunotec,
Abingdon, UK) that have been subjects of interest for many
studies. In 2015 Qiagen updated its IGRA lineup, now of-
fering a new generation of QFT-GIT: QuantiFERON-TB
Gold Plus (QFT-Plus). According to the manufacturer the
QFT-Plus offers higher sensitivity and specificity in patients
at highest risk for TB-infection and in immunocomprom-
ised patients [21]. The aim of this study was to see if this
new generation IGRA offers a plus in areas where present
IGRA products tend to struggle. We are aware of only one
paper, published independently from the producer of QFT-
Plus which investigates sensitivity and specificity of the new
generation IGRA [22]. In particular, so far, no data is avail-
able on test variability of new generation QFT-Plus in serial
testing. Therefore, the primary objective of our study was
to evaluate QFT-Plus test variability in a direct head-to-
head comparison of QFT-GIT and QFT-Plus in a cohort of
students and young professionals with a migration back-
ground currently studying at a German university or tech-
nical college.
Methods
Study design and subjects
We recruited a total of 41 participants from our partner
study in which students and young professionals with
migration background were screened for LTBI using
both IGRAs (QFT-GIT and QFT-Plus) (Gallegos Mo-
rales EN, Knierer J, Schablon A, Nienhaus A, Kersten JF:
Prevalence of Latent Tuberculosis Infection among for-
eign students tested with QuantiFERON-TB Gold In-
Tube and QuantiFERON-TB Gold Plus, submitted). All
students that were screened positive in at least one of
the two IGRAs at baseline were asked to participate in
this cohort study. 11 out of 13 students with positive
baseline results agreed to participate. Another 30 partici-
pants with negative baseline results in both IGRAs were
selected by chance. The study was conducted at univer-
sities and technical colleges in Lübeck, Germany, between
February 2016 and March 2016.
Inclusion criteria were an age of at least 18 years,
student status or having completed studies at a German
university, and a migration background. For fulfilling the
migration background criteria, participants must have
been foreign born in a country with a WHO-estimated
tuberculosis incidence of at least 10 incident cases per
100,000 inhabitants per annum (hereinafter: ≧10:100,000).
If born in a country with lower incidence, having a nation-
ality of a country with a TB incidence of at least
10:100,000 allowed participation [23]. People without a
migration background fulfilling the nationality criteria but
only having that nationality because of their parents’
nationality, were excluded.
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Some IGRA studies tend to exclude people that have
had a TST during the previous 3–6 months [17, 24]. In our
study a recent TST application was not an exclusion criter-
ion because many students, especially medicine students
or students of natural sciences, do a TST during classes at
the university. So the timeframe of the last TST applica-
tion was queried in the questionnaire. None of the partici-
pants had a TST application during the ongoing study.
Exclusion criteria were withdrawal of consent, ongoing
active TB infection or treatment for LTBI, insufficient
Interferon-gamma (IFN-γ) production in the positive
control at the first screening visit, and absence from
more than one study visit.
Questionnaire items
The standardized questionnaire was offered in two
languages: German and English. It covered information on
the participants’ study subject, work area, nationality and
country of birth, time living in Germany permanently, im-
munosuppression caused by disease or current medica-
tion, information on contact with people with active
tuberculosis, and specification of that contact. In detail we
asked for: recent participation in tuberculosis screening
and recent chest X-ray results; previous TST or IGRA re-
sults as well as BCG vaccination status (anamnestic and/
or verification by vaccination scars); own TB history and
history of treatment for active TB or LTBI.
Diagnostic methods and data collection
The new generation IGRA QFT-Plus carries a lot of its
predecessors’ characteristics but uses two antigen tubes
(TB1 and TB2) instead of one in the QFT-GIT. As in
the QFT-GIT, T-lymphocyte secreted IFN-γ is quantita-
tively measured by ELISA technique after in vitro stimu-
lation with antigens highly specific for Mycobacterium
tuberculosis.
Both tubes contain the antigens ESAT-6 and CFP-10
(TB 7.7 additionally used in the QFT-GIT tube is no
longer present in QFT-Plus tubes). The TB1 tube is de-
signed to elicit cell-mediated immune (CMI) responses
from CD4+ T-helper lymphocytes whereas the TB2 tube
additionally contains a set of peptides targeted to the in-
duction of CMI responses from CD8+ cytotoxic T-
lymphocytes [25]. The latter might potentially help to
distinguish active from latent TB and should improve
sensitivity in immunocompromised patients e.g. children
or HIV co-infected patients [21, 25].
Collection of all blood samples and care for partici-
pants were performed by two study physicians (JK,
ENGM). Weekly testing (7 +/- 1 days) with QFT-Plus
and QFT-GIT was performed in all individuals over a 4-
week period. Participants were given individual appoint-
ments to make sure that the blood was taken at the
same time of day on each visit.
As some studies suggest that variation of blood vol-
ume in the QFT tubes might be a reason for increased
test variability [26], the blood was first collected in tubes
with lithium heparin, expecting that a subsequent in-lab
transfer of the blood in the QFT tubes would secure trans-
fer of the accurate blood volume. The blood samples were
transported to the laboratory within 8 h after blood collec-
tion. QFT tubes were then inoculated manually by profes-
sional medical technicians and directly incubated in strict
adherence to the manufacturer’s instructions within one
hour after arrival of the samples at the laboratory.
IFN-γ ELISAs were performed directly after the incu-
bation on all blood samples.
As suggested in the manufacturer’s instructions QFT-
GIT results were considered positive if the IFN-γ value
was ≧ 0.35 IU/ml after correction for the negative control.
QFT-Plus results were considered positive if the IFN-γ re-
sponse after correction for the negative control was ≧ 0.35
IU/ml in one of the two TB antigen tubes (TB1 or TB2)
or if both tubes (TB1 and TB2) showed ≧ 0.35 IU/ml.
Measurement resolution and laboratory restrictions led
to a truncated interval of IFN-γ values: IFN-γ values > 10
IU/ml were leveled at 10 IU/ml; IFN-γ values <0.01 IU/ml
or negative values were leveled at 0.00 IU/ml.
Conversion was defined as the change from a negative
result (<0.35 IU/ml) in the previous visit to a positive
result (≧0.35 IU/ml) in the next visit. In line with the
above definition for QFT-Plus interpretation, it was
sufficient if the change from negative results (<0.35 IU/
ml) in both TB antigen tubes to a positive result (≧0.35
IU/ml) was achieved in one of the two TB antigen tubes
to count as a conversion. Reversion was defined as the
change from a positive result to a negative result.
All participants were offered advice and explanation of
their personal test results by the study physicians.
To rule out the possibility of active TB, participants
with a positive test result in more than one study visit
were advised to take a chest X-ray if not recently per-
formed in context of TB screening. Participants with
prior contact to a person with active TB during the last
2 years and positive results qualified for preventive
chemotherapy. They were sent to pulmonary consultants
for a second opinion and for planning and supervision
of the therapy if suitable.
Statistical analysis
Categorical data is presented as counts and correspond-
ing rates, continuous variables are presented as means,
standard deviations (SD) and ranges where appropriate.
Agreement between the two test methods (QFT-GIT
and QFT-Plus) was analyzed using Cohen’s kappa coeffi-
cient. The variance attributed to the individuals, i.e. test
reliability in the individual, was investigated for the
QFT-Plus with the intraclass correlation coefficient
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(ICC) in a 1-way design. An ICC of >0.8 is regarded as
indicative for a high agreement and therefore a low
intraindividual variance [27].
Data evaluation was performed using SPSS Version 22
(IBM Corp., Armonk, NY USA).
Results
Study population and risk factors for IGRA-positivity at
baseline
The characteristics of our study population and baseline
QFT-Plus results are presented in Table 1. Participants
had a mean age of 25.5 ± 3.6 (range: 20 to 36) years,
average time living in Germany was 3.8 ± 3.8 years
(range: 4 months to 23.6 years), and 22 participants were
born in a country with a TB incidence of ≧ 125:100,000.
Participants’ country of birth or country that allowed
participation included all six WHO-regions: Africa
(including: Cameroon, Ghana, Kenya, Nigeria, South
Africa and United Republic of Tanzania), The Americas
(including: Ecuador, Guatemala, Honduras and Mexico),
South-East Asia (including: India, Indonesia and Nepal),
Europe (including: Belarus, Lithunia, Russian Federation,
Tajikistan and Ukraine), Eastern Mediterranean (includ-
ing: Syrian Arab Republic and Yemen) and Western
Pacific (including: China, Mongolia, Philippines, Republic
of Korea and Vietnam).
Nineteen participants reported contact to a person with
active TB of which 6 (32%) had a positive QFT-Plus at
baseline with five out of six (83%) defining the TB contact
as a family member. 11 participants declared a TST appli-
cation, the average time since last TST was 5.7 years; two
of these reported a TST application during the six months
before inclusion in the study (in both cases one month
beforehand). Both had consistent IGRA results on all four
visits with full concordance between the two IGRAs; one
had consistently negative and the other showed consist-
ently positive IGRA results. Being consistently positive
this participant was classified as true positive. 30 partici-
pants were never tested with TST.
One IGRA-positive participant had a personal history
of active TB. On inclusion in our study this student was
smear- and culturally negative after completion of anti-
tuberculosis chemotherapy. None of the participants
showed signs of ongoing active TB infection at the time
of inclusion in the study.
IGRA positivity throughout the study and test intervals
All 41 participants turned up for their weekly appoint-
ments, resulting in 164 blood samples.
On visit 3, the laboratory was unable to analyze one
blood sample. This led to a total of 163 valid IFN-γ
values for each of the two IGRAs, i.e. four serial mea-
surements at weekly intervals for 40 participants and
three measurements for one participant.
Table 1 Description of study population and frequencies of





N (Col-%) N (Row-%) N (Row-%)
Gender
Female 22 (53.7) 3 (13.6) 19 (86.4)
Male 19 (46.3) 6 (31.6) 13 (68.4)
Age
20–25 years 26 (63.4) 3 (11.5) 23 (88.5)
26–36 years 15 (36.6) 6 (40.0) 9 (60.0)
Country of birth
Classified by TB-incidence
< 125:100 000 19 (46.3) 1 (5.3) 18 (94.7)
≥ 125:100 000 22 (53.7) 8 (36.4) 14 (63.6)
Classified by WHO-regions
Africa 9 (22.0) 4 (44.4) 5 (55.6)
The Americas 6 (14.6) 0 (0.0) 6 (100.0)
South-East Asia 9 (22.0) 2 (22.2) 7 (77.8)
Europe 10 (24.4) 0 (0.0) 10 (100.0)
Eastern Mediterranean 2 (4.9) 0 (0.0) 2 (100.0)
Western Pacific 5 (12.2) 3 (60.0) 2 (40.0)
Time living in Germany
< 2 years 15 (36.6) 3 (20.0) 12 (80.0)
2–10 years 25 (61.0) 6 (24.0) 19 (76.0)
> 10 years 1 (2.4) 0 (0.0) 1 (100.0)
Contact to TB
Yes 19 (46.3) 6 (31.6) 13 (68.4)
No 22 (53.7) 3 (13.6) 19 (86.4)
Type of TB contact
Relatives 8 (19.5) 5 (62.5) 3 (37.5)
Friends/acquaintances 3 (7.3) 0 (0.0) 3 (100.0)
Professional 6 (14.6) 0 (0.0) 6 (100.0)
Other type 2 (4.9) 1 (50.0) 1 (50.0)
TB in own history
Yes 1 (2.4) 1 (100.0) 0 (0.0)
No 40 (97.6) 8 (20.0) 32 (80.0)
BCG-vaccination
Yes 18 (43.9) 2 (11.1) 16 (88.9)
No 4 (9.8) 3 (75.0) 1 (25.0)
unknown 19 (46.3) 4 (21.1) 15 (78.9)
Previous TST
Positive 3 (7.3) 2 (66.7) 1 (33.3)
Negative 5 (12.2) 0 (0.0) 5 (100.0)
Unknown 3 (7.3) 0 (0.0) 3 (100.0)
No TST 30 (73.2) 7 (23.3) 23 (76.7)
aQFT-Plus result at baseline
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In one case (0.8%) the interval between tests was 6
days, 7-day interval in 107 cases (87.7%), 8-day interval
in 13 cases (10.7%), and – because of the not analyzable
blood sample – a 14-day interval in one case (0.8%).
All 11 recruited participants with initial IGRA positivity
remained positive throughout the study in at least one of
the two IGRAs. A 12th participant only showed one posi-
tive QFT-Plus result on visit 3 but reverted on the final
visit. All 12 participants with IGRA positivity throughout
the study had an LTBI risk due to their migration back-
ground: 11 participants with positive IGRA results were
born in a country with a TB incidence of ≧125:100,000
and one positive participant was born in China which is
classified as a high TB burden country by the WHO [28].
Over the whole study period nine participants showed
stable positive QFT-GIT results and 30 had stable negative
QFT-GIT results. For the QFT-Plus, eight participants
were stable positive and 29 participants were stable nega-
tive. During the 4-week study period a total number of 42
positive results in the QFT-GIT and 40 positive results in
the QFT-Plus were collected.
(Individual IGRA results and IFN-γ values for all
participants throughout the study are shown in the table
in the supplement [see Additional file 1]).
Reversions and conversions
Reversions and conversions occurred in four participants
with inconsistent results, i.e. inconsistency of dichotom-
ous IGRA test decisions during the study period (Table 2).
All four showed inconsistent QFT-Plus results and only
two of them also showed inconsistent QFT-GIT results.
For the QFT-GIT two conversions and one reversion
were detected. One conversion was stable, the other con-
version and reversion were caused by a fluctuating result:
a reversion followed by a reconversion on the subsequent
visit (pos-neg-pos-pos) (Fig. 1). The QFT-Plus had four
conversions and two reversions of which one conversion
and one reversion were based on fluctuating results (pos-
neg-pos-pos and neg-neg-pos-neg) (Fig. 2). In the QFT-
Plus two of the conversions and two reversions occurred
only because of the IFN-γ measurement crossing the
cutoff in tube TB2 (Fig. 3) and not in tube TB1 (Fig. 4).
All inconsistent results of the QFT-GIT occurred in
the same participants that showed inconsistent QFT-
Plus results during the study period.
The conversions and reversions in both IGRAs took
place within a range close to the cutoff. For the QFT-GIT
the lowest IFN-γ value that showed a conversion was 0.18
IU/ml, for QFT-Plus tube TB1 it was 0.11 IU/ml and tube
TB2 0.09 IU/ml. The highest IFN-γ value that showed a
reversion was 0.35 IU/ml for QFT-GIT and 0.64 IU/ml for
tube TB2 of QFT-Plus. No QFT-Plus reversion was caused
by crossing of the cutoff in tube TB1.
IGRA variability
For each participant four serial measurements at weekly
intervals led to a possibility of reversions and conver-
sions on three occasions. Overall, 163 valid IFN-γ values
were collected for each IGRA. On the last visit 41 blood
samples were analyzable, leaving 122 valid IFN-γ values
for each IGRA that were followed by a subsequent result
and therefore feasible for a change of the dichotomous
IGRA test result. Total numbers for every visit with
changes of IGRA results can be seen in the flow chart
Fig. 5. With a total number of 42 positive QFT-GIT
results of which 11 occurred on the final visit, 31 posi-
tive results were followed by a subsequent result and
therefore feasible for reversion. Using the number of the
above QFT-GIT reversions and conversions, a reversion
rate of 3.2% (1 of 31 possible reversions, 95% CI 0.2–
18.5%) and correspondingly calculated conversion rate
of 2.2% (2 of 91 possible conversions, 95% CI 0.4–8.5%)
was present in our study. The QFT-Plus had a reversion
rate of 6.9% (2 of 29, 95% CI 1.2–24.2%) and a conver-
sion rate of 4.3% (4 of 93, 95% CI 1.4–11.3%).
Concordance between the two IGRAs and Intraclass
Correlation (ICC)
On visits 1 and 2, in 92.7% of results (38 of 41 subjects) of
the two IGRAs were concordant, 95% on visit 3 (38 of 40)
and on the final visit the IGRA results were concordant in
Table 2 Participants with inconsistent IGRA results in the weekly blood collections
Sex No. Age IGRA Visit 1 Visit 2 Visit 3 Visit 4 Overall trend
M 9 32 QFT-Plus Neg. (0.15/0.19) Neg. (0.17/0.14) Neg. (0.14/0.09) Pos. (0.34/0.40) Inc.
QFT-GIT Pos. (0.40) Pos. (0.62) Pos. (0.66) Pos. (0.65) Pos.
M 10 20 QFT-Plus Neg. (0.24/0.20) Pos. (0.50/0.47) Pos. (0.55/0.73) Pos. (0.79/0.69) Inc.
QFT-GIT Pos. (0.35) Neg. (0.31) Pos. (0.46) Pos. (0.53) Inc.
M 11 23 QFT-Plus Pos. (0.32/0.64) Neg. (0.11/0.12) Pos. (0.46/0.40) Pos. (0.56/0.61) Inc.
QFT-GIT Neg. (0.18) Pos. (0.52) Pos. (0.47) Pos. (0.63) Inc.
M 12 25 QFT-Plus Neg. (0.08/0.08) Neg. (0.05/0.14) Pos. (0.16/0.36) Neg. (0.21/0.24) Inc.
QFT-GIT Neg. (0.04) Neg. (0.09) Neg. (0.09) Neg. (0.14) Neg.
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all of the participants (41 of 41), leading to an overall
agreement between the two IGRAs of 95.1% (155 of 163);
Kappa: 0.89 (Table 3).
Figure 6 compares values of the two QFT-Plus tubes TB1
and TB2, showing that in three occasions QFT-Plus posi-
tivity was based on crossing of the manufacturers cutoff
(0.35 IU/ml) only in tube TB2 whereas TB1 stayed under
the cutoff. Figure 7 compares values of the QFT-GIT with
QFT-Plus tube TB1 values. On six occasions the QFT-GIT
showed values over the cutoff while the TB1 value was
under the cutoff. Once the TB1 value was higher than the
cutoff while QFT-GIT stayed under it. Figure 8 depicts the
concordance between QFT-GIT and QFT-Plus Tube TB2.
On five occasions the QFT-GIT had values over the cutoff
while at the same time TB2 stayed under it. Three times
TB2 was over the cutoff while QFT-GIT was under it.
The ICC for the QFT-Plus, representing the propor-
tion of the variance that is attributed to the variation
between individuals, was 0.88. This correspondingly in-
dicates that variance in the individuals was low.
Active TB infection and chest X-ray results
None of the chest X-rays of participants with a positive
IGRA-result showed signs of ongoing active TB. Despite
Fig. 1 QFT-GIT continuous IFN-γ courses of the individual participants during the four study weeks
Fig. 2 QFT-Plus continuous IFN-γ courses using maximum IFN-γ value of the two antigen tubes
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the study physicians advice two of the participants re-
fused to take their X-ray. As stated above, none of the
participants showed clinical signs of ongoing active TB
infection so it was assumed that no participant with
active TB was taking part in the study.
The one participant formerly treated for active TB,
but now being smear- and culturally negative, showed
consistently positive results in both IGRAs.
Discussion
Our study confirms the occurrence of conversions and
reversions in both the well studied QFT-GIT and the
new generation IGRA QFT-Plus. The QFT-GIT had a
reversion rate of 3.2% and a conversion rate of 2.2%.
Both rates were slightly higher for the QFT-Plus: 6.9%
reversions and 4.3% conversions. Due to the small num-
ber of blood samples evaluated, the confidence intervals
for the variability rates of the two IGRAs compared are
large and overlap each other.
The overall agreement between the two IGRAs of
95.1% (155/163) was good (κ = 0.89). Admittedly, one
must take into account that a regression-to-the-mean
phenomenon might have led to the increased concord-
ance during the successive visits. This is caused by
Fig. 3 QFT-Plus continuous IFN-γ courses during the four study weeks of TB Antigen Tube 2 (TB2)
Fig. 4 QFT-Plus continuous IFN-γ courses during the four study weeks of TB Antigen Tube 1 (TB1)
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random fluctuation around a true mean. Each time the
same subject undergoes repeated measurement, extreme
observations might be followed by ones that are closer
to the subject’s true mean. This could lead to natural
variation looking like real change in serial testing of the
same subject [29]. Ringshausen et al. and Tagmouti et al.
identified this phenomenon as an additional source of
test variability in serial IGRA testing [8, 17], especially
when IGRA positive subjects are longitudinal followed.
As all variations took place within a narrow range
close to the manufacturers’ cutoff, the use of a border-
line zone like already proposed for the QFT-GIT might
as well be useful for the interpretation of changes
around the cutoff in the QFT-Plus. For the QFT-GIT
Ringshausen et al. in their review advocate the use of a
borderline zone from 0.2–0.7 IU/ml. The authors
suggest that subjects with borderline zone results and
suspected infection should be retested before recom-
mending preventive chemotherapy [9]. Using this defin-
ition for the QFT-Plus and defining a conversion as a
cross passing of the borderline zone from below to
above and a reversion as a cross passing from above the
borderline zone to below the borderline zone, we did
not observe a conversion or reversion. Applying this
definition for conversions will reduce the number of pre-
ventive treatments needed when a positive QFT is
observed in serial testing.
Test results of QFT-Plus for individuals were very
similar, with a high ICC of 0.88.
Furthermore it is worth noticing that in four cases
only the IFN-γ value of the antigen TB2 tube crossed
the manufacturer’s cutoff leading to conversion and
reversion in those participants. The overall number of
inconsistent results is too low to suggest that tube TB2
was the sole cause of the higher rate of variability. This
observation seems plausible because of a further source
of variation but deserves further investigation in follow-
up studies.
Overall, inconsistent IGRA results of less than 7%
occurred, which is less frequently than what can be
found in the literature. Ringshausen et al. described
reversion rates of 22.1% to 71.4% and conversion rates
of 0.7% to 14.4% in their systematic review [9].
Fig. 5 Flow chart of study population and IGRA results













1 41 9 (22.0) 10 (24.4) 3 (7.3) 92.7%
2 41 9 (22.0) 10 (24.4) 3 (7.3) 92.7%
3 40 11 (27.5) 11 (27.5) 2 (5.0) 95.0%
4 41 11 (26.8) 11 (26.8) 0 (0.0) 100%
Total 163 40 (24.5) 42 (25.8) 8 (4.9) 95.1% (κ = 0.89) Fig. 6 Concordance between the QFT-Plus tubes TB1 and TB2
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In another systematic review Zwerling et al. found 7%
to 70% of reversions and 11.6% to 21% of conversions in
serial testing of healthcare workers (HCW) in high-
incidence countries, and 11% to 33% of reversions and
1.8% to 14.4% of conversions in HCW serial testing in
low-incidence countries [6].
As our numbers, especially occurrence of reversions,
are lower, it is important to note that these studies were
undertaken with data from screening of HCWs and that
the interval between subsequent visits varied between
the studies but were in most cases longer than our
seven-day interval.
In a study undertaken in a similar timeframe to ours,
but also using HCWs as its study population and five
time points, Ringshausen et al. found 28.6% of inconsist-
ent results (inconsistency in 10 out of 35 subjects).
Comparing results of subsequent visits to baseline re-
sults, they had 50% of reversions (6 out of 12 initial posi-
tive subjects) and 17.4% of conversions (4 out of 23
initial negative subjects) [17].
King et al. in their variability study on a large cohort
of U.S. HCWs investigating the other commercially
available IGRA, the T-SPOT.TB, showed lower conver-
sion rates: 0.8% conversions and 17.6% reversions (or
1.6% conversions and 26.4% reversions if including bor-
derline zone results). Their study shows a strong correl-
ation between the risk of conversion and the reported
TB incidence rates of the state in which the HCWs were
located [30]. The lower conversion rates in the study by
King et al. could as well be inherent to the different
assay that was used. Compared to the ELISPOT based
assay the ELISA based assays like QFT-GIT and QFT-
Plus might show higher variability due to the limited
control of the number of T-cells in the vials. This was
suggested by an assay comparison concerning Cyto-
megalovirus (CMV) infection comparing CMV ELISPOT
and CMV QuantiFERON: Saldan et al. assume interassay
differences like the comparison of CMI responses in a
volume of blood in QuantiFERON assays versus a given
number of cells in ELISPOT assays to be a potential
source of variability [31].
Systematic testing of HCWs for LTBI is a main area of
use for serial IGRA testing. As stated above, most stud-
ies on IGRA variability are undertaken on HCWs with
longer intervals between blood collections. New TB
exposure at intervals between the study visits might
cause IGRA conversion. Zwerling et al. note in their
systematic review that occupational TB risk factors cor-
relate with IGRA positivity but that it remains unclear
whether occupational TB exposure is associated with
IGRA conversion [6]. In the following, Zwerling et al.
ran different studies to evaluate the impact of occupa-
tional TB exposure on IGRA conversion. Such an associ-
ation could not be shown in Canadian HCWs [24] but
was present in another study with nursing students in
India [32]. In order to eliminate TB exposure as a factor
of IGRA variability during our study, intervals between
blood collections were short and a cohort with low
probability of recent TB contact was chosen. On the
other hand untargeted systematically testing of low risk
groups could lead to higher false positive rates [2]. So
we chose a group of participants with a higher risk than
the native population in Germany (German TB inci-
dence 6.2:100,000): students with a migration back-
ground from countries with a TB incidence of at least 10
incident cases per 100,000 per year. As a matter of fact,
Fig. 7 Concordance between QFT-GIT and QFT-Plus tube TB1
Fig. 8 Concordance between QFT-GIT and QFT-Plus tube TB2
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all participants with an initial positive IGRA come from
a country with high TB incidence ≧ 125:100,000 or from a
country classified as a high TB burden country by the
WHO. Therefore it is likely that the positive results at base-
line were ‘true positive’ results. This might explain the low
reversion rate we observed compared to the HCW studies
mentioned above. However, no gold standard for LTBI test-
ing exists to which IGRA results can be compared. As no
active TB was found in our study, it is impossible to say if
positives are ‘true positives’ in respect of LTBI.
Yet all 11 participants with a positive baseline result in
one of the two IGRAs stayed positive in at least one of the
two IGRAs through all four visits. One of those 11 students
was treated for active TB and had consistently positive
results in both IGRAs. It was shown in other studies that
IGRA positivity can persist in people formerly infected with
active TB after completion of antituberculosis chemother-
apy and that IGRAs therefore are not a sufficient tool for
monitoring antituberculosis chemotherapy [33]. It seems
plausible that the other 10 participants with positive results
in both IGRAs on the final visit were indeed true positives
with regard to LTBI. All conversions in those participants
were stable conversions.
Even the 12th participant that only had one positive
QFT-Plus result on visit 3 and later reverted was born in
a high-incidence country and reported a close contact to
active TB over ten years ago (contact with a relative).
The positive QFT-Plus result might indeed be an im-
munological footprint of that former contact but because
of the unstable conversion and all-negative results in the
other visits this case was not classified as LTBI.
Still it is important to notice that reversion does not
mean that the previous QFT was false positive as
suggested by a recent study from South Africa. Andrews
et al. demonstrated that the predictive value of a positive
IGRA result is higher than the predictive value of a
negative test result, even if the test reverts to negative at
the following control. Incident tuberculosis was 8-fold
higher among QFT reverters than in participants with
all negative QFT results [34].
Strengths and limitations
Our study is the first study we are aware of that investi-
gated variability of the new generation QFT-Plus in
serial testing in a direct head-to-head comparison with
QFT-GIT.
The number of participants tested was rather small
(n = 41) but a total of 163 serial measurements were
analyzed for each IGRA. These numbers align with
similar studies on IGRA variability [17].
Choosing students with a migration background study-
ing at a German university as our study subjects gave us
an opportunity to evaluate the IGRAs in a cohort with
higher LTBI risk than the native population in a low TB
incidence setting. Therefore it is highly unlikely that our
participants had new contact to active TB during the study
period.
The students proved to be a reliable cohort with all of
the participants attending their appointments punctually.
The only missing result was caused by a blood sample
that could not be analyzed. None of the participants
dropped out of the study.
Letting individuals with a recent TST application
(less than 3 or even 6 months prior first study visit)
participate although other studies tend to exclude these
individuals due to possible IGRA boosting [17, 24]
might be a limitation of the study as well as a strength
because we investigated all of the subjects without any
censoring. Other sources also indicate no IGRA boost-
ing following TST application. These studies advise
against attributing IGRA positivity to possible boosting
induced by a previous TST [8, 35].
Conclusions
Although an initial recent study certifies the new gener-
ation IGRA QFT-Plus as delivering results with good
sensitivity and specificity [22], our study could not con-
firm improvements in the area of test variability. Inclu-
sion of an additional test tube elucidating CD8+ T-cell
response can give rise to further variability. However,
following our data the increase in variability was rather
small due to the high agreement between QFT-GIT and
QFT-Plus. Assuming that the additional tube used in the
QFT-Plus will improve sensitivity, the similarity in vari-
ability suggests that QFT-Plus has the potential to be
advantageous compared to its predecessor.
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